首页 > 最新文献

Journal of Cancer Research and Clinical Oncology最新文献

英文 中文
Correction: The role of the SOX2 gene in cervical cancer: focus on ferroptosis and construction of a predictive model. 更正:SOX2基因在宫颈癌中的作用:关注铁下垂和预测模型的构建。
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-28 DOI: 10.1007/s00432-024-06054-0
Shenping Liu, Zhi Wei, Huiqing Ding
{"title":"Correction: The role of the SOX2 gene in cervical cancer: focus on ferroptosis and construction of a predictive model.","authors":"Shenping Liu, Zhi Wei, Huiqing Ding","doi":"10.1007/s00432-024-06054-0","DOIUrl":"10.1007/s00432-024-06054-0","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"27"},"PeriodicalIF":2.7,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Race as a prognostic factor of breast mucinous carcinoma. 种族作为乳腺黏液癌的预后因素。
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-27 DOI: 10.1007/s00432-024-06035-3
Dingyuan Wang, Yang Wang, Songlin Gao, Rongshou Zheng, Guijian Wu, Jianping Wang, Can Lu, Kena Bu, Chun Zhang, Wanqing Chen, Bailin Zhang

Purpose: The rarity of breast mucinous carcinoma (BMC) makes it challenging to study the prognosis of this disease across diverse racial populations. This study aimed to leverage epidemiological data on immigrant populations to elucidate the prognostic differences in BMC patients from various racial/ethnic backgrounds. The goal was to help formulate more personalized clinical practice guidelines for the management of this rare malignancy.

Methods: The study included 208 BMC patients from China and 10,322 BMC patients from the SEER database. Clinicopathological data, treatment information, and survival outcomes were compared across different racial/ethnic groups using statistical analyses.

Results: Asian American BMC patients were younger at diagnosis and had more favorable tumor grade and stage compared to other racial groups. After adjusting for clinicopathological factors and treatments, Asian American BMC patients exhibited significantly better overall survival (OS) than black (HR = 1.53, 95% CI: 1.05-2.22, P = 0.027) and white patients (HR = 1.41, 95% CI: 1.03-1.94, P < 0.001). Specifically, non-Chinese American patients had a worse OS compared to Chinese patients (adjusted HR = 2.59, 95% CI: 1.15-5.83, P = 0.022). Chemotherapy significantly improved OS only in black BMC patients (adjusted HR = 0.52, 95% CI: 0.27-0.98, p = 0.045), but not in other racial/ethnic groups.

Conclusion: Race is an independent prognostic factor for BMC. Compared with Chinese patients, black and white American patients have a worse prognosis in terms of OS. Treatment guidelines for BMC patients should be formulated with considerations of race factors. For patients with BMC originating from China, a more conservative treatment approach may be warranted.

目的:乳腺粘液癌(BMC)的罕见性使得研究这种疾病在不同种族人群中的预后具有挑战性。本研究旨在利用移民人群的流行病学数据来阐明不同种族/民族背景的BMC患者的预后差异。目的是帮助制定更个性化的临床实践指南,以管理这种罕见的恶性肿瘤。方法:该研究包括来自中国的208例BMC患者和来自SEER数据库的10322例BMC患者。使用统计分析比较不同种族/民族的临床病理数据、治疗信息和生存结果。结果:与其他种族相比,亚裔美国人BMC患者在诊断时更年轻,肿瘤分级和分期更有利。在调整临床病理因素和治疗后,亚裔美国人BMC患者的总生存期(OS)明显优于黑人(HR = 1.53, 95% CI: 1.05-2.22, P = 0.027)和白人(HR = 1.41, 95% CI: 1.03-1.94, P)。与中国患者相比,美国黑人和白人患者在OS方面预后较差。BMC患者的治疗指南应考虑种族因素。对于来自中国的BMC患者,可能需要更保守的治疗方法。
{"title":"Race as a prognostic factor of breast mucinous carcinoma.","authors":"Dingyuan Wang, Yang Wang, Songlin Gao, Rongshou Zheng, Guijian Wu, Jianping Wang, Can Lu, Kena Bu, Chun Zhang, Wanqing Chen, Bailin Zhang","doi":"10.1007/s00432-024-06035-3","DOIUrl":"10.1007/s00432-024-06035-3","url":null,"abstract":"<p><strong>Purpose: </strong>The rarity of breast mucinous carcinoma (BMC) makes it challenging to study the prognosis of this disease across diverse racial populations. This study aimed to leverage epidemiological data on immigrant populations to elucidate the prognostic differences in BMC patients from various racial/ethnic backgrounds. The goal was to help formulate more personalized clinical practice guidelines for the management of this rare malignancy.</p><p><strong>Methods: </strong>The study included 208 BMC patients from China and 10,322 BMC patients from the SEER database. Clinicopathological data, treatment information, and survival outcomes were compared across different racial/ethnic groups using statistical analyses.</p><p><strong>Results: </strong>Asian American BMC patients were younger at diagnosis and had more favorable tumor grade and stage compared to other racial groups. After adjusting for clinicopathological factors and treatments, Asian American BMC patients exhibited significantly better overall survival (OS) than black (HR = 1.53, 95% CI: 1.05-2.22, P = 0.027) and white patients (HR = 1.41, 95% CI: 1.03-1.94, P < 0.001). Specifically, non-Chinese American patients had a worse OS compared to Chinese patients (adjusted HR = 2.59, 95% CI: 1.15-5.83, P = 0.022). Chemotherapy significantly improved OS only in black BMC patients (adjusted HR = 0.52, 95% CI: 0.27-0.98, p = 0.045), but not in other racial/ethnic groups.</p><p><strong>Conclusion: </strong>Race is an independent prognostic factor for BMC. Compared with Chinese patients, black and white American patients have a worse prognosis in terms of OS. Treatment guidelines for BMC patients should be formulated with considerations of race factors. For patients with BMC originating from China, a more conservative treatment approach may be warranted.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"25"},"PeriodicalIF":2.7,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathological characteristics and long-term prognosis of triple-negative breast cancer patients with HER2-Low expression: a retrospective propensity score-matched cohort study. her2低表达三阴性乳腺癌患者的临床病理特征和长期预后:回顾性倾向评分匹配队列研究
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-27 DOI: 10.1007/s00432-024-06069-7
Xin Liu, Kaihua Zhao, Ziyan Zhang, Meiyan Liu, Hongwu Chu, Xiao Zou

Purpose: The objective of the current research was to assess the clinicopathological characteristics and long-term prognosis of triple-negative breast cancer (TNBC) patients with human epidermal growth factor receptor 2 (HER2)-low status following breast surgery.

Methods: A total of 202 TNBC patients treated at Qingdao Central Hospital from January 2010 to December 2019 were included, comprising 71 HER2-low and 131 HER2-zero patients. Propensity score matching (PSM) was applied to minimize differences between the cohorts.

Results: HER2-low TNBC patients had lower histological grade, lower Ki-67 expression levels, and a higher prevalence of hypertension compared to HER2-zero TNBC patients. Before and after PSM, the HER2-low group consistently exhibited a lower recurrence rate and longer RFS compared to HER2-zero TNBC patients. HER2-low status was validated as an independent low-risk factor for RFS both pre-PSM (HR 0.354, 95% CI 0.178-0.706, p = 0.003) and post-PSM (HR 0.405, 95% CI 0.185-0.886, p = 0.024). No statistically significant differences in mortality rate and OS were observed, both before and after PSM.

Conclusions: HER2-low and HER2-zero TNBC patients show significant clinicopathological differences. Compared to HER2-zero, HER2-low status is linked to better long-term prognosis and serves as an independent low-risk factor for RFS in TNBC patients.

目的:本研究的目的是评估乳腺手术后人类表皮生长因子受体2 (HER2)水平低的三阴性乳腺癌(TNBC)患者的临床病理特征和长期预后。方法:选取2010年1月至2019年12月青岛市中心医院收治的TNBC患者202例,其中her2低患者71例,her2零患者131例。使用倾向评分匹配(PSM)来最小化队列之间的差异。结果:与her2 - 0 TNBC患者相比,her2 -低TNBC患者的组织学分级较低,Ki-67表达水平较低,高血压患病率较高。在PSM前后,与her2 - 0 TNBC患者相比,her2 -低组始终表现出更低的复发率和更长的RFS。her2低状态被证实为psm前(HR 0.354, 95% CI 0.178-0.706, p = 0.003)和psm后(HR 0.405, 95% CI 0.185-0.886, p = 0.024)的RFS的独立低危险因素。PSM前后的死亡率和总生存率无统计学差异。结论:her2 -低与her2 -零TNBC患者临床病理差异显著。与her2 - 0相比,her2 -低状态与更好的长期预后有关,并且是TNBC患者RFS的独立低风险因素。
{"title":"Clinicopathological characteristics and long-term prognosis of triple-negative breast cancer patients with HER2-Low expression: a retrospective propensity score-matched cohort study.","authors":"Xin Liu, Kaihua Zhao, Ziyan Zhang, Meiyan Liu, Hongwu Chu, Xiao Zou","doi":"10.1007/s00432-024-06069-7","DOIUrl":"10.1007/s00432-024-06069-7","url":null,"abstract":"<p><strong>Purpose: </strong>The objective of the current research was to assess the clinicopathological characteristics and long-term prognosis of triple-negative breast cancer (TNBC) patients with human epidermal growth factor receptor 2 (HER2)-low status following breast surgery.</p><p><strong>Methods: </strong>A total of 202 TNBC patients treated at Qingdao Central Hospital from January 2010 to December 2019 were included, comprising 71 HER2-low and 131 HER2-zero patients. Propensity score matching (PSM) was applied to minimize differences between the cohorts.</p><p><strong>Results: </strong>HER2-low TNBC patients had lower histological grade, lower Ki-67 expression levels, and a higher prevalence of hypertension compared to HER2-zero TNBC patients. Before and after PSM, the HER2-low group consistently exhibited a lower recurrence rate and longer RFS compared to HER2-zero TNBC patients. HER2-low status was validated as an independent low-risk factor for RFS both pre-PSM (HR 0.354, 95% CI 0.178-0.706, p = 0.003) and post-PSM (HR 0.405, 95% CI 0.185-0.886, p = 0.024). No statistically significant differences in mortality rate and OS were observed, both before and after PSM.</p><p><strong>Conclusions: </strong>HER2-low and HER2-zero TNBC patients show significant clinicopathological differences. Compared to HER2-zero, HER2-low status is linked to better long-term prognosis and serves as an independent low-risk factor for RFS in TNBC patients.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"24"},"PeriodicalIF":2.7,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CTSG is a prognostic marker involved in immune infiltration and inhibits tumor progression though the MAPK signaling pathway in non-small cell lung cancer. 在非小细胞肺癌中,CTSG是参与免疫浸润并通过MAPK信号通路抑制肿瘤进展的预后标志物。
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-26 DOI: 10.1007/s00432-024-06051-3
Qian Dai, Xufeng Yao, Yanke Zhang, Qian Chai, Xueyi Feng, Hongbin Zhu, Lei Zhao

Purpose: This study aims to investigate the biological roles and molecular mechanisms of Cathepsin G (CTSG) in the progression of non-small cell lung cancer (NSCLC).

Methods: Western blotting and immunohistochemistry analyses of clinical samples were performed to determine the expression levels of CTSG in patients with NSCLC. Bioinformatic analysis of clinical datasets was conducted to evaluate the correlation between CTSG and lymph node metastasis, tumor stage, and immune cell infiltration. Gain-of-function assays and tumor implantation experiments were employed to determine the effects of CTSG on malignant behaviors of NSCLC cells. Transcriptome sequencing and subsequent bioinformatic analysis were performed to explore the signaling pathways regulated by CTSG. Western blotting and qPCR were utilized to assess the influence of CTSG on the MAPK and EMT signaling pathways.

Results: CTSG is expressed at low levels and serves as a prognostic marker in NSCLC. The downregulation of CTSG expression was associated with lymph node metastasis, tumor stage, and immune cell infiltration. CTSG inhibits NSCLC cell proliferation, migration, and invasion as well as tumor growth in nude mice. There exists a significant correlation between CTSG expression and endoplasmic reticulum function, cell cycling, and the IL-17 signaling pathway. CTSG suppresses the MAPK and EMT signaling pathways in NSCLC cells. Moreover, DNA methylation and histone deacetylation have been identified as crucial mechanisms contributing to the decreased expression of CTSG.

Conclusion: CTSG inhibits NSCLC development by suppressing the MAPK signaling pathway and is also associated with tumor immunity.

目的:探讨组织蛋白酶G (Cathepsin G, CTSG)在非小细胞肺癌(non-small cell lung cancer, NSCLC)进展中的生物学作用及分子机制。方法:采用Western blotting和免疫组化方法检测非小细胞肺癌患者CTSG的表达水平。对临床数据集进行生物信息学分析,评价CTSG与淋巴结转移、肿瘤分期、免疫细胞浸润的相关性。采用功能增益法和肿瘤植入实验研究CTSG对NSCLC细胞恶性行为的影响。通过转录组测序和随后的生物信息学分析来探索CTSG调控的信号通路。Western blotting和qPCR检测CTSG对MAPK和EMT信号通路的影响。结果:CTSG低水平表达,可作为非小细胞肺癌的预后指标。CTSG表达下调与淋巴结转移、肿瘤分期、免疫细胞浸润有关。CTSG抑制裸鼠非小细胞肺癌细胞增殖、迁移、侵袭及肿瘤生长。CTSG表达与内质网功能、细胞周期、IL-17信号通路存在显著相关性。CTSG抑制非小细胞肺癌细胞中的MAPK和EMT信号通路。此外,DNA甲基化和组蛋白去乙酰化已被确定为导致CTSG表达降低的关键机制。结论:CTSG通过抑制MAPK信号通路抑制NSCLC的发展,并与肿瘤免疫有关。
{"title":"CTSG is a prognostic marker involved in immune infiltration and inhibits tumor progression though the MAPK signaling pathway in non-small cell lung cancer.","authors":"Qian Dai, Xufeng Yao, Yanke Zhang, Qian Chai, Xueyi Feng, Hongbin Zhu, Lei Zhao","doi":"10.1007/s00432-024-06051-3","DOIUrl":"10.1007/s00432-024-06051-3","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to investigate the biological roles and molecular mechanisms of Cathepsin G (CTSG) in the progression of non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>Western blotting and immunohistochemistry analyses of clinical samples were performed to determine the expression levels of CTSG in patients with NSCLC. Bioinformatic analysis of clinical datasets was conducted to evaluate the correlation between CTSG and lymph node metastasis, tumor stage, and immune cell infiltration. Gain-of-function assays and tumor implantation experiments were employed to determine the effects of CTSG on malignant behaviors of NSCLC cells. Transcriptome sequencing and subsequent bioinformatic analysis were performed to explore the signaling pathways regulated by CTSG. Western blotting and qPCR were utilized to assess the influence of CTSG on the MAPK and EMT signaling pathways.</p><p><strong>Results: </strong>CTSG is expressed at low levels and serves as a prognostic marker in NSCLC. The downregulation of CTSG expression was associated with lymph node metastasis, tumor stage, and immune cell infiltration. CTSG inhibits NSCLC cell proliferation, migration, and invasion as well as tumor growth in nude mice. There exists a significant correlation between CTSG expression and endoplasmic reticulum function, cell cycling, and the IL-17 signaling pathway. CTSG suppresses the MAPK and EMT signaling pathways in NSCLC cells. Moreover, DNA methylation and histone deacetylation have been identified as crucial mechanisms contributing to the decreased expression of CTSG.</p><p><strong>Conclusion: </strong>CTSG inhibits NSCLC development by suppressing the MAPK signaling pathway and is also associated with tumor immunity.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"21"},"PeriodicalIF":2.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occupational adjustments and work ability of young adult cancer survivors: results from the AYA-Leipzig study. 青年癌症幸存者的职业调整和工作能力:来自AYA-Leipzig研究的结果。
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-26 DOI: 10.1007/s00432-024-06050-4
Hannah Brock, Katharina Schröter, Michael Friedrich, Annekathrin Sender, Diana Richter, Anja Mehnert-Theuerkauf, Kristina Geue, Katja Leuteritz

Purpose: Adolescent and young adult cancer survivors (AYA-CS) face a long working life after treatment, yet factors related to a successful return to work remain largely unexplored. We therefore aimed to investigate the use of occupational adjustments and their impact on work ability upon return to work.

Methods: As part of the AYA-LE study, we surveyed AYA-CS (aged 18-39 at diagnosis) who returned to work and assessed work ability (Work Ability Index) as well as use and benefit of occupational adjustments. We analyzed predictors of use and benefit of occupational adjustments on average 4 years post-diagnosis using multivariate linear and logistic regression.

Results: Out of 438 AYA-CS, 389 (88.8%) returned to work after cancer diagnosis and were included in analyses. Mean work ability was M = 36.2 (SD = 6.9), 11.4% reported poor, 34.7% moderate, 41.4% good and 12.5% excellent work ability. Following treatment, 82.3% used occupational adjustments, most frequently: flexible working hours, gradual reintegration and reduced working hours. The probability of a reduction in working hours was found to be higher among older AYA-CS (≥ 30), female gender and with a fatigue index ≥ 11 (R2 = 0.073). A fatigue index < 11, elevated levels of pain and the presence of metastases/recurrence were associated with a lower benefit of reduced working hours (R2 = 0.183). Younger age (< 30) and stem cell transplant were associated with a lower benefit of support from colleagues (R2 = 0.077).

Conclusion: Our results highlight the need for targeted occupational counselling throughout the treatment and even beyond the return-to-work process, considering individual and social factors.

目的:青少年和年轻成人癌症幸存者(AYA-CS)在治疗后面临很长的工作寿命,但与成功重返工作岗位相关的因素在很大程度上仍未被探索。因此,我们旨在调查职业调整的使用及其对重返工作岗位后工作能力的影响。方法:作为AYA-LE研究的一部分,我们调查了AYA-CS(诊断时18-39岁)重返工作岗位,评估了工作能力(工作能力指数)以及职业调整的使用和受益。我们使用多变量线性和逻辑回归分析了诊断后平均4年职业调整使用和获益的预测因素。结果:在438名AYA-CS中,389名(88.8%)在癌症诊断后重返工作岗位,并被纳入分析。平均工作能力M = 36.2 (SD = 6.9), 11.4%工作能力差,34.7%工作能力一般,41.4%工作能力好,12.5%工作能力优。治疗后,82.3%的患者进行了职业调整,最常见的是:灵活的工作时间、逐渐重返社会和减少工作时间。年龄≥30岁的AYA-CS、女性和疲劳指数≥11的员工减少工作时间的概率更高(R2 = 0.073)。结论:我们的研究结果强调了在整个治疗过程中,甚至在重返工作过程之后,考虑到个人和社会因素,有针对性的职业咨询的必要性。
{"title":"Occupational adjustments and work ability of young adult cancer survivors: results from the AYA-Leipzig study.","authors":"Hannah Brock, Katharina Schröter, Michael Friedrich, Annekathrin Sender, Diana Richter, Anja Mehnert-Theuerkauf, Kristina Geue, Katja Leuteritz","doi":"10.1007/s00432-024-06050-4","DOIUrl":"10.1007/s00432-024-06050-4","url":null,"abstract":"<p><strong>Purpose: </strong>Adolescent and young adult cancer survivors (AYA-CS) face a long working life after treatment, yet factors related to a successful return to work remain largely unexplored. We therefore aimed to investigate the use of occupational adjustments and their impact on work ability upon return to work.</p><p><strong>Methods: </strong>As part of the AYA-LE study, we surveyed AYA-CS (aged 18-39 at diagnosis) who returned to work and assessed work ability (Work Ability Index) as well as use and benefit of occupational adjustments. We analyzed predictors of use and benefit of occupational adjustments on average 4 years post-diagnosis using multivariate linear and logistic regression.</p><p><strong>Results: </strong>Out of 438 AYA-CS, 389 (88.8%) returned to work after cancer diagnosis and were included in analyses. Mean work ability was M = 36.2 (SD = 6.9), 11.4% reported poor, 34.7% moderate, 41.4% good and 12.5% excellent work ability. Following treatment, 82.3% used occupational adjustments, most frequently: flexible working hours, gradual reintegration and reduced working hours. The probability of a reduction in working hours was found to be higher among older AYA-CS (≥ 30), female gender and with a fatigue index ≥ 11 (R2 = 0.073). A fatigue index < 11, elevated levels of pain and the presence of metastases/recurrence were associated with a lower benefit of reduced working hours (R2 = 0.183). Younger age (< 30) and stem cell transplant were associated with a lower benefit of support from colleagues (R2 = 0.077).</p><p><strong>Conclusion: </strong>Our results highlight the need for targeted occupational counselling throughout the treatment and even beyond the return-to-work process, considering individual and social factors.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"20"},"PeriodicalIF":2.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell transcriptomes of dissecting the intra-tumoral heterogeneity of breast cancer microenvironment. 单细胞转录组分析乳腺癌微环境肿瘤内异质性。
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-26 DOI: 10.1007/s00432-024-06015-7
Peixian Chen, Kaifeng Liang, Xiaofan Mao, Qiuyuan Wu, Zhiyan Chen, Yabin Jin, Kairong Lin, Tiancheng He, Shuqing Yang, Huiqi Huang, Guolin Ye, Juntao Gao, Dan Zhou, Zhihao Zeng

Objective: To investigate the mechanism by which heterogeneity in breast cancer developed and acted in single-cell transcriptomes.

Methods: The composition of breast cancer based on the single-cell transcriptomes of 54,055 high-quality cells from clinical specimens of 4 malignant and 4 non-malignant patients were investigated.

Results: We identified six common expression programs and six subtype-specific expression programs form malignant epithelial cells. The expression program of malignant epithelial cells exhibited activated EMT (Epithelial Mesenchymal Transition) in TME, which might indicate EMT intervention have a general therapeutic effect on various subtypes. Gene set enrichment analysis (GSEA) based on the top 50 highly NMF (non-negative matrix factorization) score genes in each program depicted the distinct function of each program in breast cancer progression. Moreover, we revealed the profound cellular heterogeneity of myeloid cell lineages in breast cancer. In macrophages, two mainly tumor associated macrophages (TAMs), TAM1 and TAM2, were also detected and the highly variable genes in TAM2 were strongly enriched in IFN-α and IFN-γ. The changes of lipid metabolism pathways in macrophages are closely related to the microenvironment of breast cancer.

Conclusion: We constructed a comprehensive single-cell transcriptome atlas of 54,055 cells from 4 malignant and 4 nonmalignant patients, providing insights into the mechanisms underlying breast cancer progression and the development of potential therapeutic strategies in breast cancer.

目的:探讨乳腺癌单细胞转录组异质性发生和作用的机制。方法:利用4例恶性和4例非恶性临床标本54055个优质细胞的单细胞转录组研究乳腺癌的组成。结果:在恶性上皮细胞中鉴定出6个常见表达程序和6个亚型特异性表达程序。恶性上皮细胞的表达程序在TME中表现出活化的上皮间充质转化(epithelial Mesenchymal Transition, EMT),这可能表明EMT干预对不同亚型的TME具有普遍的治疗效果。基因集富集分析(GSEA)基于每个程序中前50个高度NMF(非负矩阵分解)评分的基因,描述了每个程序在乳腺癌进展中的独特功能。此外,我们揭示了骨髓细胞谱系在乳腺癌中的深刻的细胞异质性。在巨噬细胞中,还检测到两种主要的肿瘤相关巨噬细胞TAM1和TAM2,并且TAM2中高度可变的基因在IFN-α和IFN-γ中强烈富集。巨噬细胞脂质代谢途径的变化与乳腺癌的微环境密切相关。结论:我们构建了来自4例恶性和4例非恶性患者的54,055个细胞的综合单细胞转录组图谱,为乳腺癌进展的机制和潜在治疗策略的发展提供了见解。
{"title":"Single-cell transcriptomes of dissecting the intra-tumoral heterogeneity of breast cancer microenvironment.","authors":"Peixian Chen, Kaifeng Liang, Xiaofan Mao, Qiuyuan Wu, Zhiyan Chen, Yabin Jin, Kairong Lin, Tiancheng He, Shuqing Yang, Huiqi Huang, Guolin Ye, Juntao Gao, Dan Zhou, Zhihao Zeng","doi":"10.1007/s00432-024-06015-7","DOIUrl":"10.1007/s00432-024-06015-7","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the mechanism by which heterogeneity in breast cancer developed and acted in single-cell transcriptomes.</p><p><strong>Methods: </strong>The composition of breast cancer based on the single-cell transcriptomes of 54,055 high-quality cells from clinical specimens of 4 malignant and 4 non-malignant patients were investigated.</p><p><strong>Results: </strong>We identified six common expression programs and six subtype-specific expression programs form malignant epithelial cells. The expression program of malignant epithelial cells exhibited activated EMT (Epithelial Mesenchymal Transition) in TME, which might indicate EMT intervention have a general therapeutic effect on various subtypes. Gene set enrichment analysis (GSEA) based on the top 50 highly NMF (non-negative matrix factorization) score genes in each program depicted the distinct function of each program in breast cancer progression. Moreover, we revealed the profound cellular heterogeneity of myeloid cell lineages in breast cancer. In macrophages, two mainly tumor associated macrophages (TAMs), TAM1 and TAM2, were also detected and the highly variable genes in TAM2 were strongly enriched in IFN-α and IFN-γ. The changes of lipid metabolism pathways in macrophages are closely related to the microenvironment of breast cancer.</p><p><strong>Conclusion: </strong>We constructed a comprehensive single-cell transcriptome atlas of 54,055 cells from 4 malignant and 4 nonmalignant patients, providing insights into the mechanisms underlying breast cancer progression and the development of potential therapeutic strategies in breast cancer.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"17"},"PeriodicalIF":2.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AKT1-Mediated NOTCH1 phosphorylation promotes gastric cancer progression via targeted regulation of IRS-1 transcription. akt1介导的NOTCH1磷酸化通过靶向调节IRS-1转录促进胃癌进展。
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-26 DOI: 10.1007/s00432-024-06039-z
Lingshan Zhou, Yuan Yang, Qian Qiao, Yingying Mi, Yuling Gan, Ya Zheng, Yuping Wang, Min Liu, Yongning Zhou

Purpose: This study aimed to investigate that AKT1-Mediated NOTCH1 phosphorylation promotes gastric cancer (GC) progression via targeted regulation of IRS-1 transcription.

Methods: The study utilized databases such as PhosphositePlus, TRANSFAC, CHEA, GPS 5.0, and TCGA, along with experimental techniques including Western Blot, co-IP, in vitro kinase assay, construction of lentiviral overexpression and silencing vectors, immunoprecipitation, modified proteomics, immunofluorescence, ChIP-PCR, EdU assay, Transwell assay, and scratch assay to investigate the effects of AKT1-induced Notch1 phosphorylation on cell proliferation, invasion and migration in vitro, as well as growth and epithelial-mesenchymal transition (EMT) in vivo.

Results: AKT1 was found to induce phosphorylation of Notch1 at the S2183 site in GC, subsequently altering the subcellular localization of Notch1-IC and promoting its nuclear translocation. The transcription factor RBPJ that binds to Notch1 transcriptionally regulated IRS-1, CDH5, TNL1, ASCL2, and LRP6. Experimental validation revealed that Notch1-IC can regulate the expression of IRS-1. Overexpression of Notch1-IC was shown to promote the proliferation, invasion, and metastasis of GC cells, while knockdown of IRS-1 partially inhibited the aforementioned effects induced by Notch1-IC overexpression. Further experiments in vitro and vivo confirmed that AKT1-induced Notch1 phosphorylation can regulate the expression of IRS-1 and promote the malignant behavior of GC, including proliferation, invasion, metastasis, and EMT, with knockdown of IRS-1 partially reversing these effects.

Conclusion: AKT1 induces the Notch1 phosphorylation and promotes the activation and nuclear translocation of Notch1-IC by targeting the regulation of IRS-1, thereby advancing the progression of GC.

目的:本研究旨在探讨akt1介导的NOTCH1磷酸化通过靶向调节IRS-1转录促进胃癌(GC)进展。方法:本研究利用PhosphositePlus、TRANSFAC、CHEA、GPS 5.0、TCGA等数据库,结合Western Blot、co-IP、体外激酶测定、慢病毒过表达和沉默载体构建、免疫沉淀、修饰蛋白组学、免疫荧光、ChIP-PCR、EdU法、Transwell法、scratch法等实验技术,研究akt1诱导的Notch1磷酸化对体外细胞增殖、侵袭和迁移的影响。以及体内生长和上皮-间质转化(EMT)。结果:AKT1可诱导GC中Notch1的S2183位点磷酸化,进而改变Notch1- ic的亚细胞定位,促进其核易位。与Notch1结合的转录因子RBPJ可调控IRS-1、CDH5、TNL1、ASCL2和LRP6的转录。实验验证表明,Notch1-IC能够调控IRS-1的表达。Notch1-IC过表达可促进胃癌细胞的增殖、侵袭和转移,而IRS-1的下调可部分抑制Notch1-IC过表达诱导的上述作用。进一步的体外和体内实验证实,akt1诱导的Notch1磷酸化可调节IRS-1的表达,促进胃癌的增殖、侵袭、转移和EMT等恶性行为,而敲低IRS-1可部分逆转这些作用。结论:AKT1通过靶向IRS-1调控诱导Notch1磷酸化,促进Notch1- ic的活化和核易位,从而促进GC的进展。
{"title":"AKT1-Mediated NOTCH1 phosphorylation promotes gastric cancer progression via targeted regulation of IRS-1 transcription.","authors":"Lingshan Zhou, Yuan Yang, Qian Qiao, Yingying Mi, Yuling Gan, Ya Zheng, Yuping Wang, Min Liu, Yongning Zhou","doi":"10.1007/s00432-024-06039-z","DOIUrl":"10.1007/s00432-024-06039-z","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate that AKT1-Mediated NOTCH1 phosphorylation promotes gastric cancer (GC) progression via targeted regulation of IRS-1 transcription.</p><p><strong>Methods: </strong>The study utilized databases such as PhosphositePlus, TRANSFAC, CHEA, GPS 5.0, and TCGA, along with experimental techniques including Western Blot, co-IP, in vitro kinase assay, construction of lentiviral overexpression and silencing vectors, immunoprecipitation, modified proteomics, immunofluorescence, ChIP-PCR, EdU assay, Transwell assay, and scratch assay to investigate the effects of AKT1-induced Notch1 phosphorylation on cell proliferation, invasion and migration in vitro, as well as growth and epithelial-mesenchymal transition (EMT) in vivo.</p><p><strong>Results: </strong>AKT1 was found to induce phosphorylation of Notch1 at the S2183 site in GC, subsequently altering the subcellular localization of Notch1-IC and promoting its nuclear translocation. The transcription factor RBPJ that binds to Notch1 transcriptionally regulated IRS-1, CDH5, TNL1, ASCL2, and LRP6. Experimental validation revealed that Notch1-IC can regulate the expression of IRS-1. Overexpression of Notch1-IC was shown to promote the proliferation, invasion, and metastasis of GC cells, while knockdown of IRS-1 partially inhibited the aforementioned effects induced by Notch1-IC overexpression. Further experiments in vitro and vivo confirmed that AKT1-induced Notch1 phosphorylation can regulate the expression of IRS-1 and promote the malignant behavior of GC, including proliferation, invasion, metastasis, and EMT, with knockdown of IRS-1 partially reversing these effects.</p><p><strong>Conclusion: </strong>AKT1 induces the Notch1 phosphorylation and promotes the activation and nuclear translocation of Notch1-IC by targeting the regulation of IRS-1, thereby advancing the progression of GC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"15"},"PeriodicalIF":2.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of the Forkhead box family protein FOXF2 in the progression of solid tumor: systematic review. 叉头盒家族蛋白FOXF2在实体瘤进展中的作用:系统综述。
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-26 DOI: 10.1007/s00432-024-06047-z
Yuzhen Zheng, Liusheng Wu, Zhenyu Hu, Hongying Liao, Xiaoqiang Li

Background: FOXF2 was reported to involve in a variety of biological behaviors that include the development of the central nervous system, tissue homeostasis, epithelia-mesenchymal interactions, regulation of embryonic development, and organogenesis.

Purpose: Understanding how FOXF2 influences the growth and development of cancer could provide valuable insights for researchers to develop novel therapeutic strategies.

Results: In this review, we investigate the underlying impact of FOXF2 on tumor cells, including the transformation of cellular phenotype, capacity for migration, invasion, and proliferation, colonization of circulating cells, and formation of metastatic nodules. In addition, we discuss the molecular mechanisms of FOXF2 in different cancers, including hepatocellular, esophageal, breast, colon, lung, prostate gland, as well as its role in embryonic development.

Conclusion: FOXF2 is a gene encoding a forkhead transcription factor belonging to the Forkhead Box family. The protein functions by recruiting activation transcription factors and basic components to activate the transcription of genes that interact with the complex. This review provides an in-depth analysis of the FOXF2's function and pleiotropic roles in cancer development and progression.

背景:据报道,FOXF2参与多种生物学行为,包括中枢神经系统的发育、组织稳态、上皮-间质相互作用、胚胎发育调控和器官发生。目的:了解FOXF2如何影响癌症的生长和发展,可以为研究人员开发新的治疗策略提供有价值的见解。结果:在这篇综述中,我们研究了FOXF2对肿瘤细胞的潜在影响,包括细胞表型的转化、迁移、侵袭和增殖能力、循环细胞的定植和转移结节的形成。此外,我们还讨论了FOXF2在不同癌症中的分子机制,包括肝细胞癌、食管癌、乳腺癌、结肠癌、肺癌、前列腺癌,以及它在胚胎发育中的作用。结论:FOXF2基因编码叉头转录因子,属于叉头盒家族。该蛋白通过招募激活转录因子和基本成分来激活与该复合体相互作用的基因的转录。这篇综述深入分析了FOXF2的功能及其在癌症发生和进展中的多效性作用。
{"title":"Role of the Forkhead box family protein FOXF2 in the progression of solid tumor: systematic review.","authors":"Yuzhen Zheng, Liusheng Wu, Zhenyu Hu, Hongying Liao, Xiaoqiang Li","doi":"10.1007/s00432-024-06047-z","DOIUrl":"10.1007/s00432-024-06047-z","url":null,"abstract":"<p><strong>Background: </strong>FOXF2 was reported to involve in a variety of biological behaviors that include the development of the central nervous system, tissue homeostasis, epithelia-mesenchymal interactions, regulation of embryonic development, and organogenesis.</p><p><strong>Purpose: </strong>Understanding how FOXF2 influences the growth and development of cancer could provide valuable insights for researchers to develop novel therapeutic strategies.</p><p><strong>Results: </strong>In this review, we investigate the underlying impact of FOXF2 on tumor cells, including the transformation of cellular phenotype, capacity for migration, invasion, and proliferation, colonization of circulating cells, and formation of metastatic nodules. In addition, we discuss the molecular mechanisms of FOXF2 in different cancers, including hepatocellular, esophageal, breast, colon, lung, prostate gland, as well as its role in embryonic development.</p><p><strong>Conclusion: </strong>FOXF2 is a gene encoding a forkhead transcription factor belonging to the Forkhead Box family. The protein functions by recruiting activation transcription factors and basic components to activate the transcription of genes that interact with the complex. This review provides an in-depth analysis of the FOXF2's function and pleiotropic roles in cancer development and progression.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"14"},"PeriodicalIF":2.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer. PEP06 (TB01)联合Trifluridine/Tipiracil (TAS-102)对人结直肠癌异种移植模型的抗癌作用
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-26 DOI: 10.1007/s00432-024-05984-z
Ruohong Lin, Jiaxing Cheng, Jinlong Zhao, Liang Zhou, Jian Li, Xinchun Yang

Background: Colorectal cancer (CRC) is the third most common cancer globally, with advanced stages presenting significant treatment challenges. Recently years, drug combination therapy has become a promising strategy for cancer treatment.

Objective: To evaluate the therapeutic efficacy of the combination of the anti-angiogenic drug PEP06 (TB01) and the cytotoxic drug Trifluridine/Tipiracil (TAS-102) in human CRC HCT-116 xenograft mouse model. And quantitative assessment of the interaction between TB01 and TAS-102 in the treatment based on pharmacological effects.

Methods: This study utilized the human CRC HCT-116 xenograft nude mouse model to evaluate the antitumor effects of TAS-102 and TB01, both as mono-therapies and in combination therapies.

Results: The combination therapy not only demonstrated significantly inhibited tumor growth in a dose-dependent manner, but also seems to reduce the common toxicity associated with such treatments, as shown by the maintenance of body weights in the treated mice.

Conclusion: The synergistic effect observed from the combined use of TAS-102 and TB01 suggests a promising new treatment avenue for refractory CRC patients, meriting further investigation and potential clinical application.

背景:结直肠癌(CRC)是全球第三大常见癌症,其晚期提出了重大的治疗挑战。近年来,药物联合治疗已成为一种很有前景的癌症治疗策略。目的:评价抗血管生成药物PEP06 (TB01)联合细胞毒药物Trifluridine/Tipiracil (TAS-102)对人CRC HCT-116异种移植小鼠模型的治疗效果。并基于药理效应定量评价TB01与TAS-102在治疗中的相互作用。方法:本研究利用人结直肠癌HCT-116异种移植裸鼠模型,评价TAS-102和TB01单独治疗和联合治疗的抗肿瘤效果。结果:联合治疗不仅以剂量依赖的方式显着抑制肿瘤生长,而且似乎还减少了与这些治疗相关的常见毒性,如治疗小鼠的体重维持。结论:TAS-102联合TB01的协同效应为难治性结直肠癌患者提供了一条新的治疗途径,值得进一步研究和临床应用。
{"title":"Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer.","authors":"Ruohong Lin, Jiaxing Cheng, Jinlong Zhao, Liang Zhou, Jian Li, Xinchun Yang","doi":"10.1007/s00432-024-05984-z","DOIUrl":"10.1007/s00432-024-05984-z","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is the third most common cancer globally, with advanced stages presenting significant treatment challenges. Recently years, drug combination therapy has become a promising strategy for cancer treatment.</p><p><strong>Objective: </strong>To evaluate the therapeutic efficacy of the combination of the anti-angiogenic drug PEP06 (TB01) and the cytotoxic drug Trifluridine/Tipiracil (TAS-102) in human CRC HCT-116 xenograft mouse model. And quantitative assessment of the interaction between TB01 and TAS-102 in the treatment based on pharmacological effects.</p><p><strong>Methods: </strong>This study utilized the human CRC HCT-116 xenograft nude mouse model to evaluate the antitumor effects of TAS-102 and TB01, both as mono-therapies and in combination therapies.</p><p><strong>Results: </strong>The combination therapy not only demonstrated significantly inhibited tumor growth in a dose-dependent manner, but also seems to reduce the common toxicity associated with such treatments, as shown by the maintenance of body weights in the treated mice.</p><p><strong>Conclusion: </strong>The synergistic effect observed from the combined use of TAS-102 and TB01 suggests a promising new treatment avenue for refractory CRC patients, meriting further investigation and potential clinical application.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"22"},"PeriodicalIF":2.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical confocal laser endomicroscopy for imaging of autofluorescence signals of human brain tumors and non-tumor brain. 临床共聚焦激光内镜对人脑肿瘤和非肿瘤脑自身荧光信号的成像。
IF 2.7 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-26 DOI: 10.1007/s00432-024-06052-2
Marlen Reichenbach, Sven Richter, Roberta Galli, Matthias Meinhardt, Katrin Kirsche, Achim Temme, Dimitrios Emmanouilidis, Witold Polanski, Insa Prilop, Dietmar Krex, Stephan B Sobottka, Tareq A Juratli, Ilker Y Eyüpoglu, Ortrud Uckermann

Purpose: Analysis of autofluorescence holds promise for brain tumor delineation and diagnosis. Therefore, we investigated the potential of a commercial confocal laser scanning endomicroscopy (CLE) system for clinical imaging of brain tumors.

Methods: A clinical CLE system with fiber probe and 488 nm laser excitation was used to acquire images of tissue autofluorescence. Fresh samples were obtained from routine surgeries (glioblastoma n = 6, meningioma n = 6, brain metastases n = 10, pituitary adenoma n = 2, non-tumor from surgery for the treatment of pharmacoresistant epilepsy n = 2). Additionally, in situ intraoperative label-free CLE was performed in three cases. The autofluorescence images were visually inspected for feature identification and quantification. For reference, tissue cryosections were prepared and further analyzed by label-free multiphoton microscopy and HE histology.

Results: Label-free CLE enabled the acquisition of autofluorescence images for all cases. Autofluorescent structures were assigned to the cytoplasmic compartment of cells, elastin fibers, psammoma bodies and blood vessels by comparison to references. Sparse punctuated autofluorescence was identified in most images across all cases, while dense punctuated autofluorescence was most frequent in glioblastomas. Autofluorescent cells were observed in higher abundancies in images of non-tumor samples. Diffuse autofluorescence, fibers and round fluorescent structures were predominantly found in tumor tissues.

Conclusion: Label-free CLE imaging through an approved clinical device was able to visualize the characteristic autofluorescence patterns of human brain tumors and non-tumor brain tissue ex vivo and in situ. Therefore, this approach offers the possibility to obtain intraoperative diagnostic information before resection, importantly independent of any kind of marker or label.

目的:分析自身荧光对脑肿瘤的描绘和诊断具有重要意义。因此,我们研究了商用共聚焦激光扫描显微内镜(CLE)系统用于脑肿瘤临床成像的潜力。方法:采用光纤探针和488nm激光激发的临床CLE系统获取组织自身荧光图像。新鲜样本来自常规手术(胶质母细胞瘤n = 6,脑膜瘤n = 6,脑转移瘤n = 10,垂体腺瘤n = 2,非肿瘤治疗耐药癫痫n = 2)。此外,术中原位无标记CLE进行了三例。对自体荧光图像进行目视检查以进行特征识别和定量。作为参考,制备组织冷冻切片,并通过无标记多光子显微镜和HE组织学进一步分析。结果:无标记CLE可获得所有病例的自体荧光图像。通过与参考文献的比较,将自身荧光结构分配到细胞的细胞质室、弹性蛋白纤维、沙粒体和血管。在所有病例的大多数图像中都发现了稀疏的标点点自身荧光,而密集的标点点自身荧光在胶质母细胞瘤中最常见。在非肿瘤样本的图像中观察到较高丰度的自体荧光细胞。肿瘤组织中以弥漫性自身荧光、纤维和圆形荧光结构为主。结论:通过一种经批准的临床设备进行无标记CLE成像,能够在体外和原位显示人类脑肿瘤和非肿瘤脑组织的特征性自身荧光模式。因此,这种方法提供了在切除前获得术中诊断信息的可能性,重要的是不依赖于任何一种标志物或标签。
{"title":"Clinical confocal laser endomicroscopy for imaging of autofluorescence signals of human brain tumors and non-tumor brain.","authors":"Marlen Reichenbach, Sven Richter, Roberta Galli, Matthias Meinhardt, Katrin Kirsche, Achim Temme, Dimitrios Emmanouilidis, Witold Polanski, Insa Prilop, Dietmar Krex, Stephan B Sobottka, Tareq A Juratli, Ilker Y Eyüpoglu, Ortrud Uckermann","doi":"10.1007/s00432-024-06052-2","DOIUrl":"10.1007/s00432-024-06052-2","url":null,"abstract":"<p><strong>Purpose: </strong>Analysis of autofluorescence holds promise for brain tumor delineation and diagnosis. Therefore, we investigated the potential of a commercial confocal laser scanning endomicroscopy (CLE) system for clinical imaging of brain tumors.</p><p><strong>Methods: </strong>A clinical CLE system with fiber probe and 488 nm laser excitation was used to acquire images of tissue autofluorescence. Fresh samples were obtained from routine surgeries (glioblastoma n = 6, meningioma n = 6, brain metastases n = 10, pituitary adenoma n = 2, non-tumor from surgery for the treatment of pharmacoresistant epilepsy n = 2). Additionally, in situ intraoperative label-free CLE was performed in three cases. The autofluorescence images were visually inspected for feature identification and quantification. For reference, tissue cryosections were prepared and further analyzed by label-free multiphoton microscopy and HE histology.</p><p><strong>Results: </strong>Label-free CLE enabled the acquisition of autofluorescence images for all cases. Autofluorescent structures were assigned to the cytoplasmic compartment of cells, elastin fibers, psammoma bodies and blood vessels by comparison to references. Sparse punctuated autofluorescence was identified in most images across all cases, while dense punctuated autofluorescence was most frequent in glioblastomas. Autofluorescent cells were observed in higher abundancies in images of non-tumor samples. Diffuse autofluorescence, fibers and round fluorescent structures were predominantly found in tumor tissues.</p><p><strong>Conclusion: </strong>Label-free CLE imaging through an approved clinical device was able to visualize the characteristic autofluorescence patterns of human brain tumors and non-tumor brain tissue ex vivo and in situ. Therefore, this approach offers the possibility to obtain intraoperative diagnostic information before resection, importantly independent of any kind of marker or label.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 1","pages":"19"},"PeriodicalIF":2.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Cancer Research and Clinical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1